Comparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia A

• Status: Recruiting
• Trial end date: 2024-06-21
• Target enrollment: 0
• Participant gender: Male

Summary

• To outcome between low dose Emicizumab and low dose prophylaxis with FVIII concentration

• To study pharmacokinetic, side effect of low dose Emicizumab

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Chulalongkorn University
• Treatments: Antibodies, Bispecific

Criteria

Inclusion Criteria:

• Severe or moderate Hemophilia A with baseline FVIII:C of <3 IU/dl or severe bleeding phenotype

• Receiving low dose FVIII prophylaxis for at least 6 months

Exclusion Criteria:

• Detectable FVIII inhibitor at screening

• Detectable FVIII inhibitor at screening Having other underlying diseases: Juvenile rheumatoid arthritis, metabolic bone diseases, or other conditions mimicking or causing joint diseases